Axsome Therapeutics, Inc.
AXSM
Classifica tra le azioni
#2362
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Prezzo delle azioni
$159.50
Capitalizzazione di mercato
$8.35B
Variazione (1 giorno)
2.37%
Variazione (1 anno)
21.20%
Paese
US
Scambia Axsome Therapeutics, Inc. (AXSM)
Categoria
Healthcare
Rapporto P/S per Axsome Therapeutics, Inc. (AXSM)
Rapporto P/S al October 2026 TTM: 10.75
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Axsome Therapeutics, Inc., il rapporto P/S attuale (TTM) è 10.75. Alla fine del 2023, era pari a 13.36.
Storico del rapporto P/S per Axsome Therapeutics, Inc. da 2013 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 10.75 | 2.28% |
| 2024 | 10.51 | -21.33% |
| 2023 | 13.36 | -78.68% |
| 2022 | 62.67 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | -6.77% |
US
|
|
| 40.55 | 277.23% |
US
|
|
| 3.96 | -63.15% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -5.61% |
NL
|
